Skip to main content
Premium Trial:

Request an Annual Quote

Proteomics Standards Initiative, Nonlinear Dynamics, Waters, Beckman Coulter, Robert Funari, Ben Bulkley, David Page

Premium

New Products

The Proteomics Standards Initiative has released version 2.5 of the PSI Molecular Interaction XML (PSI MI XML) format and controlled vocabularies. Schema, CVs, and documentation are available at http://psidev.sourceforge.net/mi/rel25/.


Nonlinear Dynamics has launched its TT900 S2S 2D gel analysis software. This product includes tools for the pre-analysis alignment of 2D electrophoresis gel images, correcting the various gel inconsistencies that occur when running and imaging 2D gels, the company said. Once aligned to a very detailed level, images can be exported for traditional gel analysis. The new technology can be used with all staining or labeling methodologies, and has been enhanced to take advantage of in-gel groups when used within the DIGE workflow.


Waters has begun shipping its MassLynx 4.1 software, which has been reconfigured to facilitate high-performance quantification and qualitative analysis so that users can process and review results, and generate reports more easily, the company said. The software also includes a new administrator toolkit that lets system administrators manage resources from a remote PC. The toolkit features software to monitor basic sample information and instrument status for all users.


Beckman Coulter recently introduced its FlowCytomix Bead-Based Multiplexing Assays, for the simultaneous detection of multiple cytokines and other analytes in drug and clinical research.

Based on a sandwich immunoassay, FlowCytomix kits use the same principles as ELISA, but deliver up to 10 analytes per well, Beckman said. The kits can be run on any flow cytometer with 488-nm excitation, including the Beckman Coulter automated FC 500 series, EPICS XL series, and Quanta systems.

 

Movers & Shakers

Beckman Coulter last week said that Robert Funari has been elected to its board of directors.

Funari is currently chairman and CEO of Crescent Healthcare, where he has been employed since 2004. Prior to that, he served as president and CEO of Syncor International. Funari also spent more than 18 years in various capacities at Baxter International. He holds an MBA from Harvard Business School and a BS in mechanical engineering from Cornell University.


Ben Bulkley, president of commercial operations for Invitrogen, was elected to the board of directors of the California Healthcare Institute, a non-profit public-policy research organization that represents California academic institutions, biotech, medical device, and pharmaceutical firms.


The Whitehead Institute's board of directors elected faculty member David Page as the institute's fourth director, Whitehead said last week.

Page was appointed as interim director in December 2004.

A biology professor at Massachusetts Institute of Technology, Page graduated from Harvard Medical School and the Harvard-MIT Health Sciences and Technology Program in 1984 with a concentration in genetics. He came to Whitehead as one of the institute's first fellows in 1984 and became a faculty member in 1986.

Page received the MacArthur Foundation Prize Fellowship in 1986, the Searle Scholar's Award in 1989, the Amory Prize from the American Academy of Arts and Sciences in 1997, and the Curt Stern Award from the American Society of Human Genetics in 2003.

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.